|
OALib Journal期刊
ISSN: 2333-9721
费用：99美元
|
|
|
|
布地奈德缓释干粉吸入剂的制备及乳糖用量的影响
, PP. 1180-1185
Keywords: 布地奈德,壳聚糖,乳糖,涡旋混合器,体外沉积
Abstract:
采用高压匀质联合喷雾干燥法制备载有布地奈德的壳聚糖微粒并考察其体外释放行为,用涡旋混合器使之与乳糖混合,以药物回收率和含量均匀度为指标考察混合速度与混合时间的影响,以药物回收率、含量均匀度、粉末流动性和体外沉积分布为指标考察乳糖用量的影响。制得微粒具有一定的体外缓释效果,可吸入组分百分比为46.0%,但流动性较差,加入10倍乳糖进行混合后,药物回收率高达96.5%,药物含量的相对标准偏差为2.5%,流动性较好,可吸入组分百分比提高至59.6%。结果表明,采用涡旋混合器可制备回收率及含量均匀度均较高的布地奈德缓释干粉吸入剂,处方具有较好的流动性,适于肺部吸入。
| [1] | liangzl,nir,zhoujy,etal.recentadvancesincontrolledpulmonarydrugdelivery[j].drugdiscovtoday,2015,20:380-389.
|
| [2] | steckelh,markefkap,tewierikh,etal.functionalitytestingofinhalationgradelactose[j].eurjpharmbiopharm,2004,57:495-505.
|
| [3] | deboerah,chanhk,pricer.acriticalviewonlactosebaseddrugformulationanddevicestudiesfordrypowderinhalation:whicharerelevantandwhatinteractionstoexpect?[j].advdrugdelivrev,2012,64:257-274.
|
| [4] | hengpws,chanlw,limlt.quantificationofthesurfacemorphologiesoflactosecarriersandtheireffectontheinvitrodepositionofsalbutamolsulphate[j].chempharmbull,2000,48:393-398.
|
| [5] | rileyt,christopherd,arpj,etal.challengeswithdevelopinginvitrodissolutiontestsfororallyinhaledproducts(oips)[j].aapspharmscitech,2012,13:978-989.
|
| [6] | marpleva,robertsdl,romayfj,etal.nextgenerationpharmaceuticalimpactor(anewimpactorforpharmaceuticalinhalertesting).parti:design[j].jaerosolmed,2003,16:283-299.
|
| [7] | zhangx,lilc,maosr.nanosuspensionsofpoorlywatersolubledrugspreparedbytop-downtechnologies[j].currpharmdesign,2014,20:388-407.
|
| [8] | vachonmg,chuliad.theuseofparticlecharacteristicstoelucidatemixhomogeneityinbinarypowderblends[j].drugdevindpharm,1998,24:961-971.
|
| [9] | kulvanichp,stewartpj.theeffectofblendingtimeonparticleadhesioninamodelinteractivesystem[j].jpharmpharmacol,1987,39:732-733.
|
| [10] | clarkemj,tobynmj,staniforthjn.theformulationofpowderinhalationsystemscontainingahighmassofnedocromilsodiumtrihydrate[j].jpharmsci,2001,90:213-223.
|
| [11] | dickhoffbhj,deboerah,lambregtsd,etal.theeffectofcarriersurfaceandbulkpropertiesondrugparticledetachmentfromcrystallinelactosecarrierparticlesduringinhalation,asfunctionofcarrierpayloadandmixingtime[j].eurjpharmbiopharm,2003,56:291-302.
|
| [12] | guchardir,freim,johne,etal.influenceoffinelactoseandmagnesiumstearateonlowdosedrypowderinhalerformulations[j].intjpharm,2008,348:10-17.
|
| [13] | dahlr.systemicsideeffectsofinhaledcorticosteroidsinpatientswithasthma[j].respirmed,2006,100:1307-1317.
|
| [14] | hulm,suny,wuy.advancesinchitosan-baseddrugdeliveryvehicles[j].nanoscale,2013,5:3103-3111.
|
| [15] | pilcerg,amighik.formulationstrategyanduseofexcipientsinpulmonarydrugdelivery[j].intjpharm,2010,392:1-19.
|
| [16] | learoydtp,burrowsjl,frenche,etal.sustaineddrugdeliveryfromchitosan-basedrespirablespraydriedpowders[j].respirdrugdeliv,2006,2:441-443.
|
| [17] | learoydtp,burrowsjl,frenche,etal.chitosan-basedspray-driedrespirablepowdersforsustaineddeliveryofterbutalinesulfate[j].eurjpharmbiopharm,2008,68:224-234.
|
| [18] | learoydtp,burrowsjl,frenche,etal.sustaineddeliverybyleucine-modifiedchitosanspray-driedrespirablepowders[j].intjpharm,2009,372:97-104.
|
| [19] | pourshahabps,gilanik,moazenie,etal.preparationandcharacterizationofspraydriedinhalablepowderscontainingchitosannanoparticlesforpulmonarydeliveryofisoniazid[j].jmicroencapsul,2011,28:605-613.
|
| [20] | lihy,birchallj.chitosan-modifieddrypowderformulationsforpulmonarygenedelivery[j].pharmres,2006,23:941-950.
|
| [21] | zhoujy,zhangl,maosr.recentprogressondrypowderinhalationofproteinsandpeptides[j].actapharmsin(药学学报),2015,50:814-823.
|
| [22] | zhangx,guanj,nir,etal.preparationandsolidificationofredispersiblenanosuspensions[j].jpharmsci,2014,103:2166-2176.
|
| [23] | sebtit,vanderbistf,amighik.evaluationofthecontenthomogeneityanddispersionpropertiesoffluticasonedpicompositions[j].jdrugdelivscitech,2007,17:223-229.
|
| [24] | levnp,thithh,robinse,etal.drypowderinhalers:studyoftheparametersinfluencingadhesionanddispersionoffluticasonepropionate[j].aapspharmscitech,2012,13:477-484.
|
Full-Text
|
|
Contact Us
service@oalib.com QQ:3279437679 
WhatsApp +8615387084133
|
|
